BMTC Group (TSE:GBT) Stock Price Crosses Below 50-Day Moving Average – What’s Next?
Global Blood Therapeutics: Pfizer Acquisition Signals Increasing M/A Deals
GLOBAL BLOOD THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Global Blood Therapeutics, Inc. - GBT
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates AAWW, GBT, CYBE, AVLR
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates GBT, AVLR, CYBE, SBCF
Get ready for more merger mania in pharma sector the rest of the year
Global Blood (GBT) to be Acquired by Pfizer, Misses on Earnings
Pfizer is acquiring Global Blood Therapeutics
Pfizer to buy Global Blood Therapeutics for US$5.4bn
SHAREHOLDER ALERT: Weiss Law Investigates Global Blood Therapeutics, Inc.
Why Global Blood Therapeutics Stock Was Trouncing the Market Today
GBT Stock Alert: Pfizer Is Officially Acquiring Global Blood Therapeutics
Pfizer Inks $5.4 Billion Deal To Acquire Global Blood Therapeutics
Pfizer Buys Global Blood Therapeutics. How the Deal Could Solve Pipeline Worries.
Why Pfizer (PFE) Is Buying Global Blood Therapeutics (GBT) For $5.4 Billion
Pfizer reaches $5.4B deal for Global Blood Therapeutics
Pfizer confirms to acquire Global Blood Therapeutics for $5.4 billion in deal that gives it access to sickle-cell disease treatment
Pfizer to buy Global Blood Therapeutics in $5.4 billion deal
Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology
Pfizer agrees to buy Global Blood Therapeutics in deal valued at $5.4 billion: WSJ
Why Global Blood Therapeutics Stock Is Vaulting Higher Today
Pfizer in Talks to Buy Global Blood Therapeutics: Report
WSJ: Pfizer considering buying Global Blood Therapeutics for roughly $5 billion
Pfizer in advanced talks to buy Global Blood Therapeutics for $5 billion - WSJ
Strength Seen in Global Blood (GBT): Can Its 41.4% Jump Turn into More Strength?
Why Global Blood Therapeutics Stock Is Soaring Today
Global Blood Therapeutics shares jump 34% after Bloomberg report about 'takeover interest'
Earnings Preview: Global Blood Therapeutics (GBT) Q2 Earnings Expected to Decline
Global Blood (GBT) Initiates Phase II Study on SCD Candidate
5 Top Biotech Stocks To Watch In July 2022
Why Global Blood Therapeutics Trended Upward Today
Global Blood Therapeutics: Powerhouse Of The Future
7 No-Brainer Biotech Stocks to Add to Your Buy List
Global Blood's (GBT) Candidates for SCD Get Two FDA Tags
GBT to Host Investor Conference Call on Friday, June 10 and Participate in Upcoming Investor Conferences
Global Blood (GBT) Thrives on Oxbryta, Overdependence a Woe
Global Blood (GBT) Q1 Loss Narrower Than Expected, Revenues Lag
Global Blood Therapeutics Inc. (GBT) CEO Ted Love on Q1 2022 Results - Earnings Call Transcript
Global Blood Therapeutics (GBT) Reports Q1 Loss, Lags Revenue Estimates
Global Blood Therapeutics: Hitting A Growth Inflection
Global Blood (GBT) Up 15.4% Since Last Earnings Report: Can It Continue?
Global Blood Therapeutics: Changing My Strategy After Recent Earnings
GBT Announces Participation in Upcoming Investor Conferences
Global Blood's (GBT) Q4 Earnings Miss Mark, Revenues Rise Y/Y
Global Blood Therapeutics, Inc. (GBT) CEO Ted Love on Q4 2021 Results - Earnings Call Transcript
Global Blood Therapeutics (GBT) Reports Q4 Loss, Tops Revenue Estimates
Drug/Biotech Stocks' Q4 Earnings on Feb 23: BMRN, BHC & More
GBT to Announce Fourth Quarter and Full Year 2021 Financial Results on Wednesday, February 23, 2022
Global Blood Therapeutics' Oxbryta Scores European Approval For Sickle Cell Disease